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Short-course R-CHOP followed by 90Y-Ibritumomab tiuxetan
in previously untreated high-risk elderly diffuse large B-cell
lymphoma patients: 7-year long-term results
V Stefoni1, B Casadei1, C Bottelli2, G Gaidano3, C Ciochetto4, MG Cabras5, M Ansuinelli6, L Argnani1, A Broccoli1, L Gandolfi1,
C Pellegrini1 and PL Zinzani1
An update at 7 years was conceived for our multicenter phase II study in which 55 elderly high-risk untreated diffuse large B-cell
lymphoma patients were treated with 90Y-ibritumomab tiuxetan after a short course of rituximab, cyclophosphamide, doxorubicin,
vincristine and prednisolone (R-CHOP) as long-term follow-up analyses of this combined therapeutic modality are lacking. The
overall response rate to the entire regimen was 80%, including 73% (40/55) of complete response (CR) rate and 7% (4/55) of partial
response rate. At the time of writing, 24/55 (43.6%) patients experienced a progression disease and 20 of 40 (50%) patients who
obtained a CR are still alive in continuous CR. With a median follow-up of 7 years, the disease-free survival was 43.3% and the
progression-free survival was 36.1%. The overall survival at 7.9 years was 38.9% (27 deaths mainly because of lymphoma). Two
patients developed secondary hematological malignancies, an acute myeloid leukemia and a myelodysplastic syndrome, at 4 and 3
years from radioimmunotherapy, respectively. Our data confirm the feasibility, efficacy and safety of four cycles of R-CHOP followed
by radioimmunotherapy consolidation even in the long term: this combination allows dispensing less chemotherapy in a frail group
of patients without invalidating response quality and duration.
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INTRODUCTION
The radiosensitivity of lymphomas, such as in particular the local,
specific targeted delivery of radiation radioimmunotherapy (RIT),
is an interesting therapeutic option for lymphoma patients. RIT
represents an attractive alternative approach for several reasons.
First, lymphoma is known to be radiosensitive; second, radiolabeled
antibodies can kill target lymphoma cells via both immunological
lysis and release of β-rays from isotopes attached to the
antibodies; third, unconjugated antibodies, such as rituximab,
cannot kill lymphoma cells if the patient’s immune system is
abnormal, decreased expression of the target antigen is present or
the tumor is difficult to approach, whereas RIT can kill tumor cells
via a cross fire or bystander effect.
Encouraging results of RIT in low-grade lymphomas also led to
its investigation as a possible therapy in aggressive non-Hodgkin’s
lymphoma. Although high-dose chemotherapy followed by
peripheral stem cell transplantation is a recommended standard
in cases with a partial response or relapsing diffuse large B-cell
lymphoma (DLBCL), many patients are not eligible for this
procedure because of advanced age or comorbidities. Thus, RIT
may be an interesting alternative therapeutic option for this
subset of patients.
RIT, in particular the 90Y-ibritumomab tiuxetan (90Y-IT), has
demonstrated efficacy in relapsed/refractory DLBCL, with promis-
ing response rates and durable response.1–3 In the initial phase I–II
trials, responses were seen in 43% of the 14 patients with DLBCL,
including complete remission (CR) in 29%.1 Gordon et al.4
provided additional data supporting the safety and the efficacy
of 90Y-IT in patients with DLBCL: for 12 patients who had
a median of two prior regimens and who were enrolled in this
phase I–II trial, the response rate was 58%, including 33% CRs.
A multicenter phase II study has assessed the role of 90Y-IT
in 104 elderly patients with relapsed or refractory DLBCL who
were not eligible for high-dose treatment, mainly because of
advanced age.3 The overall response rate was 44% and was
noted to be higher in patients who did not have prior therapy
with rituximab compared with those who had been previously
treated in first line with rituximab and chemotherapy.
In addition, data from phase II studies conducted in DLBCL and
in mantle cell lymphoma suggested that 90Y-IT is also effective
as consolidation treatment after chemotherapy or chemoimmuno-
therapy.5–8 One of these represented our experience: a phase II
study in 55 high-risk elderly patients treated in first line with an
abbreviated (four cycles than six) course of rituximab, cyclopho-
sphamide, doxorubicin, vincristine and prednisolone (R-CHOP)
followed by 90Y-IT consolidation.8
Long-term evaluations of both efficacy and safety are now
needed to best integrate and place this option into current elderly
DLBCL patient treatment algorithms. The first report we published
referred to efficacy, safety and outcomes at 18 months:8 we now
present the updated results of this study after a median follow-up
of 7 years.
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Fifty-five elderly patients (aged 465 years or 60–65 years, but not eligible
for high-dose therapy with autologous stem cell transplantation) with
high-risk DLBCL were enrolled between December 2006 and October 2008
at 7 Italian institutions. The criteria for patient eligibility have been
previously reported.8 Briefly, patients had to be previously untreated and
with stage II (with bulky disease), stage III or stage IV DLBCL,9 expressing
the CD20 antigen; they had to have a World Health Organization (WHO)
performance status ⩽ 2 and a high intermediate or high age-adjusted
International Prognostic Index score.10
All the patients underwent a full medical history, physical examination,
complete blood tests, computed tomography (CT) scan of neck, chest,
abdomen and pelvis, whole-body positron emission tomography (PET)
scan and a bone marrow biopsy. Patient characteristics are summarized in
Table 1. All patients were notified of the investigational nature of this study
and signed a written informed consent approved in accordance with
institutional guidelines, including the Declaration of Helsinki; the study was
approved by each institutional review board.
Study design
Treatment schedule was represented by the standard R-CHOP chemother-
apy every 21 days for 4 cycles; standard doses of 375 mg/m2 rituximab,
750 mg/m2 cyclophosphamide, 50 mg/m2 doxorubicin and 1.4 mg/m2
(maximum total dose of 2.0 mg) vincristine were administered intrave-
nously on day 1; 100 mg/day prednisone was given orally for 5 days for
each cycle, starting from day 1. After the completion of the fourth cycle of
R-CHOP regimen, patients were restaged by CT scan, PET scan and bone
marrow biopsy. Patients were eligible for 90Y-IT if at least in partial
response (PR) after induction, with normal platelet and granulocyte counts
and a bone marrow infiltration ⩽ 25%.
After the restaging procedures, eligible patients received one course of
90Y-IT within 12 weeks. It consisted of an infusion of rituximab at 250 mg/m2
on day 1 and a subsequent infusion at the same dose on day 8; this
second infusion of rituximab was then followed by a weight-based dose of
90Y-IT, administered at the dose of 11.1 MBq/kg (0.3 mCi/kg) for patients
with pretreatment platelet counts ranging from 100×109 to 149×109/l, and
14.8 MBq/kg (0.4 mCi/kg) for those with counts of 150×109/l or higher (90Y-
IT was routinely administered on an outpatient basis).
Follow-up procedures
Strict follow-up procedures were shared among the investigational sites
at the time of the start of the study. The original protocol was amended to
extend follow-up until 9 years from end of treatment. Disease status was
evaluated again 3 months after RIT through physical examination, bone
marrow biopsy (if still positive after induction chemoimmunotherapy), CT
and PET scan; other clinically relevant information, such as the develop-
ment of febrile neutropenia, the use of antibiotics or granulocyte-colony
stimulating factor or blood transfusion during cytopenia and the presence
of any extra-hematologic toxicity, were recorded.
Patients’ follow-up assessment included: blood count and physical
examination every 3–4 months for the first 2 years and then every
6 months for the following 3 years, CT scan every 6 months for the first 2
years, followed by physical examination and annual imaging studies with
CT or PET/CT up to 9 years from treatment completion. The determination
of tumor response was based on the revised response criteria for
malignant lymphoma.11
End points
Endpoints of long-term efficacy were progression-free survival, disease-free
survival and overall survival. Overall survival was calculated from start of
R-CHOP treatment to the date of death because of any cause and was
censored at the last date the patient was known to be alive. Disease-free
survival was calculated for CR patients from first documentation of
response to the date of relapse or death because of lymphoma or acute
toxicity of treatment, whereas progression-free survival was calculated for
all patients from the start of treatment to relapse or death because of any
cause.11 End points of late toxicity were the incidence and the time of
occurrence of secondary malignancy both hematologic and nonhemato-
logic. The crude incidence of secondary malignancies was calculated as the
proportion of patients diagnosed with secondary malignancy in the entire
study population. Analyses were conducted on an intention-to-treat basis.
RESULTS
At the time of reassessment after 4 cycles of R-CHOP-21, overall
response rate was 89%, with 32 out of 55 (58%) patients achieving
a CR and 17 out of 55 (31%) patients achieving a PR; the remaining
6 patients had progressive disease. Out of 55 patients (more
specifically, all the patients with CR and 16 patients with PR), 48
were deemed eligible for subsequent consolidation with 90Y-IT.
The remaining patient with PR showed a lymphoma progression
2 weeks before radioimmunotherapy, and was then considered
ineligible for consolidation treatment.
At the end of the entire treatment regimen (4 cycles of R-CHOP
regimen plus 90Y-IT), 40 out of 55 (73%) patients obtained CR and 4
subjects achieved PR. In the specific instance of when patients who
were in CR right after R-CHOP maintained their disease status, 8 PR
patients improved the response from partial to complete, 4 patients
remained in PR and the other 4 PR had a disease progression.
All patients completed the scheduled follow-up period. At a
median follow-up of 84 months (range, 12–95 months), the 7-year
progression-free survival was estimated to be 36.1%, with 35 events
on an intention-to-treat basis (Figure 1). The 7-year disease-free
survival was 43.3% (Figure 2) and the 7-year overall survival was
estimated to be 38.9% (Figure 3), with 27 deaths.
Please refer to the previous publication regarding the toxicity of
the regimen.8 Regarding the late hematological side effects,
secondary malignancies occurred in 2 (3.6%) patients: one reported
Table 1. Patient characteristics (N= 55)







Bulky disease, N (%)
Yes 8 (14.5)
No 47 (85.5)







aa-IPI score, N (%)
High intermediate (2) 30 (55)
High risk (3) 25 (45)
Abbreviations: aa-IPI, age-adjusted International Prognostic Index; LDH,
lactate dehydrogenase.









Figure 1. Progression-free survival.
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myelodysplastic syndrome and the other secondary acute myeloid
leukemia, developed after 36 and 48 months following RIT,
respectively (the patient with acute myeloid leukemia died).
Currently, 20 patients (50%) are in continuous CR after45 years
of follow-up. Twenty-four (20 CR and 4 PR) patients relapsed
during the follow-up period and all died because of lymphoma
progression. All the 24 relapsed patients underwent a second-line
treatment and 3 of them are now in CR, whereas all the other had
a brief response (o12 months) or no response to subsequent
therapies. Autologous stem cell transplantation was attempted in
3 out of 24 patients: the attempt failed in two subjects, whereas
the third patient is currently in CR after autologous stem cell
transplantation.
DISCUSSION
Despite markedly superior outcomes in first-line treatment following
the addition of rituximab to the CHOP regimen, with dose-dense/
dose-intense regimens also displaying a potential role,12–16 the
prognosis for DLBCL patients aged 460 years still remains poor.
At least 30 to 50% of these patients with an advanced-stage disease
will fail to attain a remission with primary therapy, or will experience
disease relapse after achieving a remission.
As early results have indicated that 90Y-IT consolidation has
a favorable tolerability profile, with low infection rates and
a manageable hematologic toxicity, we carried out this study
with CHOP plus rituximab followed by 90Y-IT in untreated elderly
DLBCL patients, also reducing the number of CHOP cycles from six
to four. The aim was to utilize all the therapeutic approaches—
chemotherapy, immunotherapy, RIT—reducing conventional che-
motherapy and probably its related toxicity, hematologic and
nonhematologic, in elderly patients.
Independently by the different front-line treatment, it should be
very important to have an update on the long-term follow-up
of these studies because the disease course of elderly high-risk
DLBCL patients is characterized by a high rate of relapse.12–16 For this
reason, this report updated long-term efficacy and toxicity results of
this sequential treatment and it represents, among the other
published data on the role of 90Y-IT consolidation in DLBCL, the first
long-term analysis.
With a median follow-up of 84 months, the 7-year disease-free
survival was 43.3%, and thus means that 20/40 patients are still in
continuous CR after 45 years in a subset of high-risk elderly
DLBCL patients: it is possible to observe a real curve plateau after
5 years, suggesting that a proportion of patients may be salvaged.
Regarding late toxicity, we observed 3% of myelodysplastic
syndrome/acute myeloid leukemia. The crude incidence of
treatment-related myelodysplastic syndrome/acute myeloid leuke-
mia has been reported to range from 0 to 12% with conventional
dose chemotherapy or radiotherapy, and our 3% is within this
range.17 In the long-term update of the LNH-98.5 trial comparing
DLBCL treated with CHOP with R-CHOP, 10.8% of patients
developed another malignancy since the enrollment.18 Thus, no
difference can be acknowledged in the safety profile between
R-CHOP alone and R-CHOP followed by RIT. Rate of mobilization
failure in our population is two thirds, but it is difficult to draw any
conclusion with these small numbers or to make any inference
about the involvement of RIT in this issue.
Considering the long-term update of the LNH-98.5 trial
comparing DLBCL treated with CHOP with R-CHOP, we achieved
same long-term results.18 To note, a lower incidence of secondary
malignancy in our sample occurred. We registered a 50%
conversion rate from PR to CR after RIT with, in addition, these
patients still being in CR; in the challenging group of elderly
patients this feature could prevent the need of further treatments.
Although the pivotal study of R-CHOP regimen in advanced
elderly DLBCL patients utilized eight cycles of chemotherapy,14
now many experts choose a six-cycle approach as standard
treatment, relying principally on the German experience that
demonstrated the equivalence of six versus eight cycles of
R-CHOP given every 14 days.12
On the basis of the long-term update of our data, there is
confirmation on the role of 90Y-IT in elderly high-risk DLBCL
patients. In addition, this sequential treatment is characterized by
the reduction in the number of chemotherapy courses with
subsequent abatement of its related toxicity, both hematologic
and nonhematologic, in a frail subset of patients.
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Figure 2. Disease-free survival.









Figure 3. Overall survival.
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